天津医药

天津医药 ›› 2022, Vol. 50 ›› Issue (2): 177-181.doi: 10.11958/20212082

• 临床研究 • 上一篇    下一篇

芪参益气滴丸对高血压合并冠心病患者心血管保护作用的临床研究

张颖，邵独婧，刘晓罡，赵英强，刘玉洁
  

  1. 1天津市胸科医院心内科（邮编300222）；2天津中医药大学第二附属医院心内科
  • 收稿日期:2021-09-09 修回日期:2021-12-19 出版日期:2022-02-15 发布日期:2022-02-15
  • 通讯作者: 邵独婧 E-mail:shaodujing@163.com
  • 作者简介:部分统计见二修
  • 基金资助:
    天津市卫生健康委员会中医药重点领域科研项目（2019005）

Clinical study of cardiovascular protective effect of Qishen yiqi dropping pills on patients with hypertension complicated by coronary heart disease #br#

ZHANG Ying, SHAO Dujing, LIU Xiaogang, ZHAO Yingqiang, LIU Yujie #br#   

  1. 1 Department of Cardiology, Tianjin Chest Hospital, Tianjin 300222, China; 2 Department of Cardiology, Second Affiliated
    Hospital of Tianjin University of TCM
  • Received:2021-09-09 Revised:2021-12-19 Published:2022-02-15 Online:2022-02-15

PDF (PC)

2739

摘要： 目的 观察芪参益气滴丸对高血压合并冠心病患者的血压、血脂、炎性因子、心绞痛症状及主要不良心脏 事件发生率的影响。方法 纳入高血压合并冠心病患者192例并按随机数字表法分为2组，每组96例。对照组予以 标准的冠心病治疗及降压药物治疗，研究组在标准治疗基础上加用芪参益气滴丸，1次0.5 g，3次/d。比较2组患者 治疗前后的收缩压（SBP）、舒张压（DBP）、总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C），超敏C反应蛋白（hs-CRP）、 白细胞介素（IL）-6、西雅图心绞痛评价量表（SAQ）症状相关维度（躯体受限程度、心绞痛稳定状态、心绞痛发作情况、 治疗满意程度评分）及主要不良心脏事件发生率等差异。结果 2组治疗后SBP、DBP、TC、LDL-C、hs-CRP及IL-6均 低于治疗前（P＜0.01），躯体受限程度、心绞痛稳定状态、心绞痛发作情况及治疗满意程度评分均高于治疗前（P＜ 0.05）。治疗后研究组患者SBP、DBP、TC、LDL-C、hs-CRP、主要不良心脏事件发生率均低于对照组（P＜0.05），躯体 受限程度、心绞痛稳定状态、心绞痛发作情况及治疗满意程度评分均高于对照组（P＜0.01）。结论 对于高血压合并 冠心病患者，在给予标准的西医治疗方案后加用芪参益气滴丸可以起到更有效降压、控制血脂、减轻炎症反应、改善 患者症状的作用，进而降低心血管事件发生风险。

关键词: 冠心病, 高血压, 血脂异常, 炎症, 芪参益气滴丸, 主要不良心脏事件

Abstract: Objective To observe the influences of Qishen yiqi dropping pills on blood pressure, blood lipid, inflammatory factors, anginal symptoms and major adverse cardiovascular events in patients with hypertension complicated by coronary heart disease. Methods Data of 192 patients with hypertension complicated by coronary heart disease were retrospectively analyzed. Patients were randomly divided into two groups, 96 for each group. The control group were given standard treatment of coronary artery disease and hypertension. The experimental group were given Qishen yiqi dropping pills (0.5 g once, three times/d) combined with standard treatment of coronary artery disease and hypertension. Changes of systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), low- density lipoprotein cholesterol (LDL-C), C-reactive protein (hs-CRP), interleukin 6 (IL-6), scores of symptom dimensions of Seattle angina pectoris scale (SAQ) including physical limitation, anginal stability, anginal frequency, treatment satisfaction and the incidence rate of major adverse cardiovascular events before and after treatment were compared between the two groups. Results Data of SBP, DBP, TC, LDL-C, hs-CRP and IL-6 were significantly decreased after treatment compared with that of before treatment (P＜0.01), and scores of physical limitation, anginal stability, anginal frequency and treatment satisfaction were significantly increased after treatment in the 2 groups (P＜0.05). After 1 year treatment, SBD, DBP, the levels of TC, LDL-C, hs-CRP and the incidence rate of major adverse cardiovascular events were significantly lower in the experimental group than those of the control group (P＜0.05). The scores of physical limitation, anginal stability, anginal frequency and treatment satisfaction were significantly higher in the experimental group than those of the control group (P＜0.01). Conclusion For patients with hypertension complicated by coronary heart disease, Qishen yiqi dropping pills can play a more effective role in lowering blood pressure, reducing levels of blood lipid and inflammation, and improving anginal symptoms and consequently reducing incidence rate of major adverse cardiovascular events, on the basis of standard Western medicine therapy.

Key words: coronary disease, hypertension, dyslipidemias, inflammation, Qishen yiqi dropping pills, major adverse cardiac events